Bloomberg the Company & Products

Bloomberg Anywhere Login

Bloomberg

Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.

Company

Financial Products

Enterprise Products

Media

Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000

Communications

Industry Products

Media Services

Follow Us


Last $2.86 USD
Change Today +0.16 / 5.93%
Volume 157.4K
MELA On Other Exchanges
Symbol
Exchange
NASDAQ CM
Berlin
As of 8:10 PM 03/26/15 All times are local (Market data is delayed by at least 15 minutes).

mela sciences inc (MELA) Snapshot

Open
$2.65
Previous Close
$2.70
Day High
$2.90
Day Low
$2.65
52 Week High
03/27/14 - $6.60
52 Week Low
12/31/14 - $1.11
Market Cap
17.3M
Average Volume 10 Days
459.0K
EPS TTM
$-2.92
Shares Outstanding
6.0M
EX-Date
--
P/E TM
--
Dividend
--
Dividend Yield
--
Current Stock Chart for MELA SCIENCES INC (MELA)

Related News

No related news articles were found.

mela sciences inc (MELA) Related Businessweek News

No Related Businessweek News Found

mela sciences inc (MELA) Details

MELA Sciences, Inc., a medical device company, designs, develops, and commercializes a non-invasive point-of-care instrument to aid in the detection of melanoma. The company’s principal product, MelaFind, consists of a hand-held component that emits light of multiple wavelengths to capture digital data from clinically atypical pigmented skin lesions, which is then analyzed utilizing classification algorithms trained on its proprietary database of melanomas and benign lesions to provide information to assist in the management of the patient’s disease, including information useful in the decision of whether to biopsy the lesion. MELA Sciences, Inc. offers its product to dermatologists. The company was formerly known as Electro-Optical Sciences, Inc. and changed its name MELA Sciences, Inc. in April 2010. MELA Sciences, Inc. was founded in 1989 and is based in Irvington, New York.

45 Employees
Last Reported Date: 03/17/14
Founded in 1989

mela sciences inc (MELA) Top Compensated Officers

No compensation data is available at this time for the top officers at this company.

Executives, Board Directors

mela sciences inc (MELA) Key Developments

MELA Sciences, Inc. Presents at 8th Annual OneMedForum 2015, Jan-13-2015 02:00 PM

MELA Sciences, Inc. Presents at 8th Annual OneMedForum 2015, Jan-13-2015 02:00 PM. Venue: San Francisco Marriott Marquis, Parc 55 Wyndham, Union Square, San Francisco, California, United States.

MELA Sciences, Inc. Announces Executive Changes

MELA Sciences, Inc. announced that its Board of Directors has named Michael R. Stewart, as the company's next President and Chief Executive Officer, effective December 15. Mr. Stewart, who joined the MELA Sciences Board of Directors in August 2014, will remain a member of the board. Stewart replaces Rose Crane, who has resigned as President and CEO and member of the Board of Directors, effective immediately. Stewart served as president, chief executive officer and board member of NASDAQ-traded Surgical Laser Technologies, Inc. from 1999 until its sale in 2002 to global medical device and skin health company PhotoMedex.

MELA Sciences, Inc. Announces Unaudited Earnings Results for the Third Quarter and Nine Months Ended September 30, 2014

MELA Sciences, Inc. announced unaudited earnings results for the third quarter and nine months ended September 30, 2014. For the quarter, the company announced net revenues of $217,902 compared to $107,707 for the same period a year ago. Operating loss was $4,000,837 compared to $6,206,247 for the same period a year ago. Net loss was $2,287,862 compared to $7,404,427 for the same period a year ago. Basic and diluted net loss per common share was $0.44 compared to $1.72 for the same period a year ago. On a monthly basis, cash used in operations averaged $1.2 million during the third quarter of 2014. For the nine months, the company announced net revenues of $540,695 compared to $396,206 for the same period a year ago. Operating loss was $12,991,181 compared to $19,724,189 for the same period a year ago. Net loss was $9,641,410 compared to $21,337,798 for the same period a year ago. Basic and diluted net loss per common share was $1.89 compared to $5.10 for the same period a year ago. Net cash used in operating activities was $14,668,421 compared to $15,513,449 for the same period a year ago. Nine months 2014 results were impacted by a cumulative $7.2 million benefit from a change in the fair value of the company’s outstanding liability for warrants accounted for as derivatives, partially offset by $3.4 million in liquidated damages from the February 2014 financing and $0.5 million in interest expense. The improvement in the company’s operating loss is more reflective of the company’s operating activities and resulted from its cash conservation and cost reduction activities.

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
MELA:US $2.86 USD +0.16

MELA Competitors

Market data is delayed at least 15 minutes.

Company Last Change
Lucid Inc $0.55 USD 0.00
Curis Inc $2.58 USD +0.03
Mauna Kea Technologies €5.12 EUR -0.11
Optiscan Imaging Ltd A$0.07 AUD +0.001
Verisante Technology Inc C$0.11 CAD 0.00
View Industry Companies
 

Industry Analysis

MELA

Industry Average

Valuation MELA Industry Range
Price/Earnings NM Not Meaningful
Price/Sales 20.7x
Price/Book 0.9x
Price/Cash Flow NM Not Meaningful
TEV/Sales NM Not Meaningful
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact MELA SCIENCES INC, please visit www.melasciences.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.